RDHL (Redhill Biopharma) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma ROE % Adjusted to Book Value?

Redhill Biopharma's ROE % for the quarter that ended in Jun. 2024 was 0.00%. Redhill Biopharma's PB Ratio for the quarter that ended in Jun. 2024 was 193.07. Redhill Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was 0.00%.

Redhill Biopharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Redhill Biopharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma ROE % Adjusted to Book Value Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-21.49

-9.31

-56.86

Negative Equity

Redhill Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Jun24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	Negative Equity	81.17	-	-

Competitive Comparison of Redhill Biopharma's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redhill Biopharma's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's ROE % Adjusted to Book Value falls into.

Redhill Biopharma ROE % Adjusted to Book Value Calculation

Redhill Biopharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	13.88
	=	Negative Equity

Redhill Biopharma's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	193.07
	=	0.00%

Redhill Biopharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.